Treatment of severe persistent asthma with IL-6 receptor blockade

J Allergy Clin Immunol Pract. May-Jun 2019;7(5):1639-1642.e4. doi: 10.1016/j.jaip.2019.02.043. Epub 2019 Mar 15.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acetates / therapeutic use
  • Adrenal Cortex Hormones / therapeutic use
  • Anti-Asthmatic Agents / therapeutic use
  • Anti-Bacterial Agents / therapeutic use
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Asthma / drug therapy*
  • Asthma / genetics
  • Asthma / physiopathology
  • Azithromycin / therapeutic use
  • Budesonide, Formoterol Fumarate Drug Combination / therapeutic use
  • Child
  • Child, Preschool
  • Drug Resistance
  • Forced Expiratory Volume
  • Humans
  • Immunoglobulins, Intravenous / therapeutic use
  • Immunologic Factors / therapeutic use
  • Interleukin-4 Receptor alpha Subunit / genetics
  • Male
  • Prednisolone / therapeutic use
  • Quinolines / therapeutic use
  • Severity of Illness Index
  • Theophylline / therapeutic use
  • Vital Capacity

Substances

  • Acetates
  • Adrenal Cortex Hormones
  • Anti-Asthmatic Agents
  • Anti-Bacterial Agents
  • Antibodies, Monoclonal, Humanized
  • Budesonide, Formoterol Fumarate Drug Combination
  • IL4R protein, human
  • Immunoglobulins, Intravenous
  • Immunologic Factors
  • Interleukin-4 Receptor alpha Subunit
  • Quinolines
  • Azithromycin
  • Prednisolone
  • Theophylline
  • tocilizumab
  • montelukast